The 2026–2030 patent cliff (Eliquis, Opdivo, Revlimid) shrinks the base faster than the Growth Portfolio + pipeline can refill it
One-line thesis. BMY is a cheap, high-yield, cash-generative pharma trading at 16× trailing / ~9× forward earnings and a ~10% free-cash-flow yield — but the low multiple is the market correctly pricing a shrinking revenue base: consensus has sales falling from ~$48B (2025) toward ~$37B (2030) as Eliquis (2028 US LOE), Opdivo and Revlimid lose exclusivity. It is a Watch: attractively priced for income, but with no growth, no expert conviction, and a base case that is roughly dead-money-plus-dividend unless the pipeline (Cobenfy, Camzyos, Breyanzi) surprises.
◆ Synthos call — HoldBMY is a solid business largely reflected at ~$60 — fine to keep, no reason to chase; it gets interesting again below ~$51.
Downside Risk (lower = safer)
5/10 · Moderate
Cheap (16× P/E, 11× EV/EBITDA) & low beta 0.24, but 2.5× net-debt/EBITDA and a shrinking-revenue patent cliff.
Growth Quality
3/10 · Low
Revenue set to DECLINE ~4%/yr through 2030 on Eliquis/Opdivo LOE; EPS erodes despite buybacks — low-quality "melting-ice-cube-plus-pipeline."
Exponential Potential
2/10 · Low
Negative organic growth, decelerating, mega-cap — no exponential case; the story is defense, not offense.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Bristol-Myers Squibb makes big-selling medicines — the blood thinner Eliquis, the cancer drug Opdivo, and a lineup of newer oncology and heart drugs. It throws off a lot of cash and pays a fat 4.3% dividend.
The problem is a "patent cliff." Several of its biggest drugs are losing their patent protection over the next few years, which lets cheaper copies flood in. Because of that, Wall Street expects the company's total sales to shrink, not grow, through 2030. That is exactly why the stock looks cheap — you're paying a low price for a business that is expected to get smaller before its newer drugs can refill the hole.
Our verdict is Watch: it's not expensive, and the dividend is real, but there's no growth engine and no expert on our panel making the bull case. Own it for income if you must, in a small size — don't mistake "cheap" for "growing."
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle of the road). The stock is cheap and barely moves with the market (very low beta), which cushions it — but it carries a fair amount of debt and its sales are declining, so it's not risk-free.
Growth Quality 3/10 (poor). The core business is shrinking. It's profitable and cash-rich, but that's a melting ice cube with a good pipeline taped to the side.
Exponential Potential 2/10 (very low). This is a defensive, shrinking-then-stabilizing story. There is no realistic path to it doubling or tripling from here.
The one big worry: the patent cliff empties the tank faster than the new drugs can refill it — leaving a smaller, lower-earning company a few years out.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = BMY · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$58.13
Market cap$119B
P/E trailing3×
P/E FY26E / FY27E9× / 9×
EV / Sales3.2×
EV / EBITDA11.2×
Gross margin68.7%
Net margin15.0%
Dividend yield4.32%
Beta0.235
52-wk range$43 – $62
RSI(14)55
50 / 200-DMA$57 / $54
12-mo return+22% (SPY +21%)
Street target$63 ($40–$75)
Analyst grades19 Buy · 20 Hold · 2 Sell
FMP ratingB+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on BMY · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Bristol-Myers Squibb (NYSE: BMY) is a ~140-year-old global biopharmaceutical company (founded 1887, HQ Princeton NJ, ~34,100 employees, CEO Christopher Boerner). Its portfolio spans oncology, hematology, cardiovascular, immunology and neuroscience. Fiscal year ends December 31.
Management now frames the business as two buckets, and this framing is the whole story:
Growth Portfolio (~$6.2B in Q1'26, +12%): the newer drugs meant to carry the future — Opdivo/Opdivo Qvantig, Camzyos (heart), Breyanzi (CAR-T), Reblozyl (anemia), Cobenfy (schizophrenia — a genuine new launch), Opdualag, Sotyktu, Krazati.
Legacy Portfolio (~$5.3B in Q1'26, −6%): the cash cows now facing generics — Eliquis (still the single largest product), Revlimid (collapsing on generics), Pomalyst, Sprycel, Abraxane.
Revenue mix (FY2025, from filings):
By product (FY25): Eliquis $14.44B (30% of revenue) · Opdivo $10.05B · Orencia $3.71B · Revlimid $2.95B (falling fast) · Yervoy $2.90B · Pomalyst $2.73B · Reblozyl $2.33B · Opdualag $1.19B · Camzyos $1.07B · Breyanzi $1.36B · Cobenfy $0.16B (new). Concentration risk is stark: Eliquis + Opdivo = ~51% of revenue, and both face LOE (loss of exclusivity) this decade.
By geography (FY25 filing): United States ~$33.3B (~69%) · Rest-of-world/other ~$14.9B. US-concentrated, so exposed to US drug-pricing policy (IRA Medicare negotiation — Eliquis is a named drug).
The strategic question the whole thesis rests on: can the Growth Portfolio + pipeline (Cobenfy in neuroscience, Camzyos in cardiology, Breyanzi/Reblozyl in heme) refill the hole left by Eliquis (2028 US LOE), Revlimid (already eroding), and Opdivo before revenue troughs.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of BMY in the Synthos knowledge base.total_claims = 0; zero net-bullish voices, zero cautionary voices, zero traceable claim_ids. Unlike our conviction-track names, no independent expert on our panel is on record with a signed view on Bristol-Myers Squibb.
What that means for this note: the verdict, scores and fair-value range below are fundamentals- and quant-driven only — built from FMP financials, analyst consensus estimates, the segment data and management's own SEC-filed guidance. We make no appeal to expert conviction because we honestly have none to cite. Readers should weight this as a data-model call, not a crowd-of-experts call. (House rule: we cite only real claim_ids; there are none, so we cite none.)
The Street's own tally — 0 Strong Buy, 19 Buy, 20 Hold, 2 Sell, consensus "Hold" — is consistent with our Watch: a cheap, well-run, but structurally challenged pharma that the sell-side is not excited about either.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Cheap (16× trailing, 11× EV/EBITDA), ~10% FCF yield and beta 0.24 cushion the downside; but net-debt/EBITDA 2.5× and a declining revenue base offset the low multiple. Max drawdown −28% shows it's not bulletproof.
Growth Quality
3 · Poor
Revenue is projected to fall from ~$48B (2025) to ~$37B (2030E); EPS erodes from ~$6.3 (2026E) to ~$4.8 (2030E) despite buybacks. High ROE (39%) is flattered by leverage. This is managed decline, not quality growth.
Exponential Potential
2 · Very Low
Negative organic growth, decelerating, $119B cap. No credible multibagger path. The entire bull case is "decline is slower than feared + pipeline surprises," which is stabilization, not exponential.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range.
Case
Key assumptions
Fair value
Bull
Growth Portfolio + Cobenfy/Camzyos/Breyanzi outrun the LOE erosion; revenue troughs shallower (~$42B) and re-accelerates; market re-rates a "growth-is-back" pharma to ~12× FY27E EPS ~$6.15 + net cash return.
~$78 (+34%)
Base(our anchor)
Estimates roughly hit — FY26E EPS $6.32, revenue declines mid-single-digits toward 2028; a shrinking-but-cash-rich pharma holds a ~9.5× FY26E multiple, with the ~4.3% dividend doing the heavy lifting on total return.
~$60 (+3%)
Bear
Eliquis 2028 LOE + IRA price cut bites harder; Opdivo erodes; pipeline disappoints; revenue troughs near ~$36B and the market prices continued decline at ~7× depressed EPS ~$5.
~$42 (−28%)
Synthos fair value = the base case, ~$60 (+3%), with the full $42–$78 span as the honest range. Our base sits essentially at the Street's $62.6 consensus — we don't see meaningful mispricing here, which is itself the point: the stock is cheap because the earnings power is set to erode, and the price roughly reflects that. This is a tracked call.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). BMY is neither — it is a defensive, shrinking-base value stock:
Forward growth is NEGATIVE: consensus revenue CAGR FY25→FY30E is about −5% ($48B → $36.8B). EPS declines from ~$6.32 (2026E) to ~$4.78 (2030E), a ~−7%/yr slide, only partially masked by buybacks. There is no growth to compound.
Acceleration (2nd derivative): the decline steepens mid-decade as Eliquis hits its 2028 US LOE — 2026E $47.3B → 2027E $46.3B → 2028E $41.0B → 2029E $37.5B. The cliff is a step-down, not a gentle glide.
Room to run: at a $119B cap the constraint isn't TAM, it's the direction of the business. A value name shrinking its top line has no room-to-run engine; the ceiling is a re-rating (multiple up) if decline proves shallower, not unit growth.
The only real optionality is the pipeline: Cobenfy (first novel schizophrenia mechanism in decades — genuine upside if it scales), Camzyos (cardiology, +97% in Q1'26 off a small base), and Breyanzi/Reblozyl in hematology. These are why the score is a 2 and not a 0 — but they refill a hole, they don't create exponential growth.
Exponential Potential: Very Low (2/10). Own BMY, if at all, for income and cheapness, explicitly not for growth. This honest framing is why it sits in the value/income sleeve, never the Core-growth or Degen tiers.
Revenue: FY25 $48.19B, essentially flat vs FY24 $48.30B (and vs FY23 $45.01B). Top line has plateaued at ~$48B and is guided/modeled to decline from here. Q1'26 $11.49B, +3% reported (+1% ex-FX).
Margins: gross 68.7% TTM, EBITDA margin 28.4% TTM, net 15.0% TTM. GAAP was distorted in 2024 by a large in-process-R&D writeoff (FY24 GAAP EPS was −$4.41 on Karuna/acquisition charges); the clean/normalized earnings power is the ~$6 non-GAAP EPS the company guides to.
Earnings: FY25 net income $7.05B, EPS $3.46 GAAP ($3.56 TTM). The 2024 GAAP loss was an accounting artifact of acquisition accounting, not operational collapse — Q1'26 non-GAAP EPS was $1.58.
Cash flow (the real strength): FY25 operating CF $14.16B, capex only −$1.31B, free cash flow $12.85B — a ~10% FCF yield on the market cap. Capex-light and highly cash-generative. This funds the dividend ($5.0B) and debt paydown ($5.2B) with room to spare.
Balance sheet: total debt $47.1B, cash $10.2B, net debt ~$36.9B, net-debt/EBITDA 2.5× TTM. Elevated (from the ~$14B Karuna deal and other M&A) but serviceable — interest coverage 12× and they paid down $5.2B of debt in FY25. Not a fortress, but investment-grade and de-levering.
Returns: ROE 39% (flattered by leverage and a thin equity base), ROIC ~13.5%, ROCE ~18.5% — genuinely good returns on capital, which is the value case.
6. Valuation — cheap, but cheap for a reason
BMY is unambiguously cheap on trailing and forward numbers: 16.3× trailing EPS, ~9.2× FY26E, EV/EBITDA 11.2×, EV/S 3.2×, ~10% FCF yield, 4.3% dividend yield, price/book 5.9×. On a PEG or DCF screen it looks like a bargain. The rating model scores DCF 5/5.
The catch is the E is shrinking. A forward P/E that falls then rises across the estimate years (9.2× FY26E → 9.4× FY27E → 12.1× FY30E at a flat price) is the tell: the multiple looks lower near-term because near-term EPS is highest, and the denominator erodes as the cliff bites. A low multiple on declining earnings is not necessarily cheap — it can be a value trap. The honest read: you are paid ~10% FCF yield and 4.3% dividend to wait, but you need the pipeline to arrest the decline for the multiple to re-rate. Street targets (context): consensus $62.6, high $75, low $40 — our ~$60 base sits right in the middle, deliberately un-heroic. This is a priced-fairly-for-a-declining-pharma situation, not a mispriced compounder.
7. Technicals (computed from EOD price history)
Trend: mildly up. $58.13 sits above the 50-DMA ($56.95) and 200-DMA ($54.02), and the 50 is above the 200 (constructive posture). MACD +0.11 (marginally positive).
Location:−7% off the 52-week high ($62.37), +36% off the 52-week low ($42.60). But note the max drawdown of −28% from peak over the window — this stock has had real air pockets.
Momentum: RSI(14) 55 — neutral, neither overbought nor oversold. No stretched-entry signal either way.
Relative strength: BMY +22.4% 12-mo vs SPY +20.6% — roughly in line with the market over a year, but −5.8% 3-mo vs SPY +13.7% and well behind QQQ (+30% 12-mo). A defensive laggard that had a decent year on the low-beta bid, now cooling.
Read: technicals are neutral-to-mildly-constructive and consistent with a range-bound value name — no momentum thrust, no breakdown. Nothing here changes the fundamentally-driven Watch.
8. Moat & competitive position
BMY's moat is narrow and eroding by design: individual drugs have patent-protected monopolies while on-patent, but the moat is the patent, and the patents are expiring. Eliquis (co-marketed with Pfizer) is the anchor and faces US LOE in 2028 plus IRA Medicare price negotiation (it is a named drug). Opdivo faces biosimilar/LOE pressure late-decade. Revlimid is already in generic collapse (from $9.98B in 2022 to $2.95B in 2025). The durable assets are R&D capability, a large commercial/manufacturing footprint, and a pipeline engine — but "we can keep inventing new drugs" is a capability, not a moat in the Buffett sense.
Peer set (FMP-listed, market cap): Pfizer $139B (the closest large-pharma comp, similar cliff dynamics), GSK $107B, Sanofi $104B, Vertex $134B, Zoetis $31B, plus healthcare-services names FMP lumps in (CVS $134B, Cigna $76B, Elevance $91B, HCA $91B, McKesson $92B — not true pharma comps). Against Pfizer and GSK, BMY screens similarly cheap with similar patent-cliff overhangs; against a Vertex (durable CF franchise) or a growth pharma, it screens as the value/declining end of the spectrum.
9. Management, capital allocation & guidance
Capital allocation: cash-return-and-de-lever. FY25 returned $5.0B in dividends (4.3% yield, a long dividend-growth track record) and paid down $5.2B of debt; buybacks were minimal in FY25 (heavier in prior years). The big swing has been M&A — the ~$14B Karuna acquisition (which brought Cobenfy) and others drove the leverage up and the 2024 GAAP loss. This is a "buy the pipeline" strategy — appropriate given the cliff, but it converts balance-sheet room into IPRD risk.
Insider activity: the recent Form-4 flow (through 2026-07-02) is routine director deferred-share-unit awards and option exercises — no cluster of alarming discretionary open-market selling in the sampled window. Neutral signal.
Management's own guidance (SEC 8-K, 2026-04-30 earnings release — half-weighted, self-interested by design): management reaffirmed 2026 guidance of revenue $46.0–47.5B and non-GAAP EPS $6.05–6.35, and said both revenue and EPS are "trending toward the upper end of the ranges." They cited Growth Portfolio revenue +12% to $6.2B (Camzyos, Breyanzi, Reblozyl the drivers) offsetting a −6% Legacy Portfolio. Note the guided 2026 revenue range ($46–47.5B) is below FY25's $48.2B — management's own numbers confirm the top line is flat-to-down. We take this as a real earnings release (it discusses revenue, guidance and outlook in detail) and weight it at half, per house rule.
10. Catalysts & what to watch
Next earnings: 2026-07-30 (Q2'26; Street EPS $1.62, revenue ~$11.7B). Key lines: Growth Portfolio revenue trajectory and whether management holds/raises the "upper end" of 2026 guidance.
Cobenfy (schizophrenia): uptake curve and label-expansion data (Alzheimer's psychosis, adjunctive) — the single biggest positive swing factor for the base.
Eliquis: 2028 US LOE countdown and IRA-negotiated price (effective 2026) — the biggest negative structural driver.
Camzyos / Breyanzi / Reblozyl: continued Growth Portfolio ramp — the refill engine.
Capital allocation: further M&A (adds pipeline but re-levers) vs. debt paydown; dividend growth.
Thesis tripwires (what would change the call): an upgrade to Buy — Tactical if Cobenfy scales fast and Growth Portfolio growth clearly outpaces Legacy erosion (revenue trough shallower/earlier than modeled); a downgrade to Avoid if the pipeline stalls and revenue heads toward the low-$30Bs with a dividend at risk.
11. Key risks
Patent cliff (structural, the core risk): Eliquis (2028 US LOE + IRA price cut), Opdivo (late-decade), Revlimid (already collapsing). ~51% of revenue is in two products facing LOE. Consensus already models revenue falling to ~$37B by 2030.
Pipeline dependency: the entire re-rating case hinges on Cobenfy/Camzyos/Breyanzi refilling the hole — new-drug launches are high-variance.
Leverage: net-debt/EBITDA 2.5× into a declining EBITDA base is riskier than the same ratio on a growing one; further M&A would push it higher.
US drug-pricing policy: ~69% US revenue, with Eliquis a named IRA Medicare-negotiation drug — direct policy exposure.
Value-trap risk: a low multiple on eroding earnings can stay low or fall further; "cheap" is not a catalyst.
No expert conviction: zero KB coverage means no independent thesis corroborates (or challenges) the model — lower confidence than our covered names.
12. Verdict, position sizing & monitoring
Watch. BMY is a well-run, deeply cash-generative, cheap, high-yield pharma — and the market has priced it exactly as what it is: a business whose revenue is set to shrink through 2030 as its biggest drugs go off patent, with a pipeline that may or may not refill the hole. There is no expert conviction in the Synthos KB to lean on, the Street itself is at "Hold," and our own base-case fair value (~$60) sits right at consensus (~$62.6) — meaning we see no compelling edge, up or down, at today's price. That is the definition of a Watch, not a Buy.
Sizing (if owned at all): income/value satellite, ≤2–3% — held for the 4.3% dividend and ~10% FCF yield, with explicit acknowledgment that total return likely comes from the coupon, not the price. Not a growth allocation.
What would make it a Buy: a clear signal (two-plus quarters) that Growth-Portfolio + Cobenfy momentum is outrunning Legacy erosion, i.e. the revenue trough is shallower/sooner than modeled — then it re-rates from value trap to turnaround at Tactical.
Monitoring: re-score each earnings print (next 2026-07-30) against the guidance "upper end" and the Growth-vs-Legacy split. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $58.13.
Single biggest risk: the 2026–2030 patent cliff empties the base faster than the pipeline refills it.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of BMY in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no expert conviction is claimed or cited. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here there is nothing to reconcile.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: the 2026 guidance ($46–47.5B revenue, $6.05–6.35 non-GAAP EPS, trending to upper end) is management's own SEC-filed words, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").